Printed From BioPortfolio.com
Nuvectra Provides Update on Virtis FDA PMA Submission
11:40 EST 30 Jan 2019 | Investing News Network
Nuvectra (NASDAQ:NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company’s pre-market approval (PMA) application for its Virtis Sacral Neuromodulation (SNM) system has been extended beyond the expiration of the FDA’s 180-day review period. As quoted in the press release: … Continued
The post Nuvectra Provides Update on Virtis FDA PMA Submission appeared first on Investing News Network.
Original Article: Nuvectra Provides Update on Virtis FDA PMA Submission
More From BioPortfolio on "Nuvectra Provides Update on Virtis FDA PMA Submission"
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
Quick Search
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn